


Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

FEE TRANSMITTAL
for FY 2001

Patent fees are subject to annual revision.



Complete if Known

#8 ATTACe

Total amount of payment	(\$2,280.00)	Filing Date	March 14, 2000		
		First Named Inventor	Soppet, et al.		
		Examiner Name	Monshipouri, M.		
		Group Art Unit	1652		
		Attorney Docket Number	PF178D2		
METHOD OF PAYMENT (CHECK ONE)					
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:					
Deposit Account Number 08-3425					
Deposit Account Human Genome Sciences, Inc. Name					
<input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17					
<input type="checkbox"/> Applicant claims small entity status					
See 37 CFR 1.27					
2. <input type="checkbox"/> Payment Enclosed: <input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input checked="" type="checkbox"/> Other					
Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425					
FEE CALCULATION					
1. BASIC FILING FEE					
Large Fee Code	Entity Fee (\$)	Small Entity Fee Code	Fee Description	Fee Paid	
101	710	201	355 Utility filing fee		
106	320	206	160 Design filing fee		
107	490	207	245 Plant filing fee		
108	710	208	355 Reissue filing fee		
114	150	214	75 Provisional filing fee		
Subtotal (1)				\$	
2. EXTRA CLAIM FEES					
Total claims	114	- 20**	94	Fee from below 18.00 \$1,692.00	
Indep.claims	10	- 3**	7	84.00 \$ 588.00	
Multiple Dependent				\$	
Large Fee Code	Entity Fee (\$)	Small Entity Fee Code	Fee Description		
103	18	203	9 Claims in excess of 20		
102	80	202	40 Independent claims in excess of 3		
104	270	204	135 Multiple dependent claim		
108	80	209	40 **Reissue independent claims over original patent		
110	18	210	9 **Reissue claims in excess of 20 and over original patent		
Subtotal (2)				\$2,280.00	
3. ADDITIONAL FEES				FEE CALCULATION (CONTINUED)	
Large Entity Fee Code	Fee (\$)	Small Entity Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late non-provisional filing fee or cover sheet	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920	112	920	Requesting publication of SIR prior to Examiner action	
113	1,840	113	1,840	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive -unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	481	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	190	169	900	Request for expedited examination of a design application	
Other fee (specify):					
Other fee (specify):					
*Reduced by Basic Filing Fee Paid					
Subtotal (3)				\$	
10/15/2001 TJOHNS04 00000001 083425 09525041					
Submitted By				01 FC:103	1692.00 CH
Name (Print/Type) Jonathan L. Klein				02 FC:102	588.00 CH
Signature: <i>Jonathan L. Klein</i>				Registration No.: 41,119	Complete (if applicable)
				Telephone	301-251-6015
				Date	October 9, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#81508
TD13101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Soppet, et al.

Serial No.: 09/525,041

Filed: March 14, 2000

Title: Colon Specific Gene and Protein

Group Art Unit: 1652

Examiner: Monshipouri, M.

Attorney Docket No.: PF178D2

RECEIVED
TECH CENTER 1600/2900
OCT 11 2001

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AP listed on the two attached Forms PTO/SB/08. Copies of references AD, AE, AF, AO, and AP are enclosed. References AD and AF were cited to Applicants in a Supplemental European Search Report (reference AO) in connection with a corresponding foreign application. Reference AE is a published PCT Application corresponding to the present application.

Copies of references AB, AC, AG, AH, AI, AJ, and AK, and AN were submitted by Applicants or cited by the Examiner in connection with U.S. Patent Application Serial No. 08/468,413 filed June 6, 1995, now issued as U.S. Patent Number 5,861,494, to which the instant application claims priority under 35 U.S.C. § 120. Additionally, copies of references AA, AL and AM were submitted by Applicants or cited by the Examiner in connection with related U.S. Patent Application Serial No. 09/162,508 filed September 29, 1998, now issued as U.S. Patent Number 6,080,722, to which the instant application claims priority under

35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the files of U.S. Patent Application Serial Nos. 08/468,413 and 09/162,508 for copies of the above-listed references. Applicants will supply copies on request.

Pursuant to 37 C.F.R. § 1.98(a)(3), Applicants herein note that reference AF (publication DE 4321944 A1) is a foreign language publication which was cited to the Applicants in a Supplemental European Search Report (reference AO). Applicants also note that reference AF (publication DE 4321944 A1) was cited as a priority document in reference AP (PCT publication WO 95/00851). Applicants herein respectfully refer the Examiner to the English language abstract in reference AP for a concise explanation of reference AF.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 9, 2001


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone: 301-251-6015

JKE/DAS/lc/kp